Regulation of cholesterol metabolism by dietary plant sterols

Current Opinion in Lipidology

Volumn 10, Issue 1, 1999, Pages 9-14

  Miettinen, Tatu A ^a   Gylling, Helena ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CAROTENE; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHYTOSTEROL;

CHOLESTEROL METABOLISM; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; METABOLIC REGULATION; PRIORITY JOURNAL; REVIEW; VITAMIN BLOOD LEVEL;

CHILD; CHOLESTEROL; ESTERS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INTESTINAL ABSORPTION; MALE; PLANTS; RANDOMIZED CONTROLLED TRIALS; STEROLS;

EID: 0033005959     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199902000-00003     Document Type: Review

References (54)

1. Pollak OJ, Kritchevsky D. Sitosterol. In: Monographs on atherosclerosis. Vol. 1. Basel: Karger; 1981.
2. Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E, Serum cholesterol lowering by sitostanol ester margarine in a mildly hypercholesterolemic random population. N Engl J Med 1995; 333:1308-1312.
3. Miettinen TA, Gylling H. Sitostanol-ester margarine. In: New technologies for healthy foods and nutraceuticals. Yalpani M (editor). Westborough, MA: ATL Press; 1997. pp. 71-83.
4. Gylling H, Miettinen TA. New biologically active lipids in food, health food and pharmaceuticals. In: Proceedings of 19th Nordic Lipid Symposium. Georg Lambertsen (editor). Bergen: Lipidforum; 1997. pp. 81-86.
5. Miettinen TA, Gylling H. Serum cholesterol lowering properties of plant sterols. In: Proceedings of COST 916. 2nd Workshop: bioactive inositol phosphatesand phytosterols in foods. Göteborg, Sweden; 1998, in press. This study illustrates the mechanisms by which plant stanol esters lower serum cholesterol and how they change the fecal elimination of cholesterol while having no effect on bile acids.
6. Pegell KH. The importance of sitosterol and sitosterolin in human and animal nutrition. S Afr J Sci 1997; 93:263-268.
7. Jones PJH, MacDougall DE, Ntanios F, Vanstone CA. Dietary phytosterols as cholesterol-lowering agents in humans. Can J Physiol Pharmacol 1997; 75:217-227.
8. Pollak OJ. Reduction of blood cholesterol in man. Circulation 1953; 7:702-706.
9. Lees RS, Lees AM. Effects of sitosterol therapy on plasma lipid and lipoprotein concentrations. In: Lipoprotein metabolism. Greten H (editor). Springer Verlag; 1976. pp. 119-124.
10. Lees AM, Mok HYI, Lees RS, McCluskey MA, Grundy SM. Plant sterols as cholesterol-lowering agents; clinical trials in patients with hypercholesterolemia and studies of sterol balance. Atherosclerosis 1977; 28:325-338.
11. Mattson FH, Grundy SM, Crouse JR. Optimizing the effect of plant sterols on cholesterol absorption in man. Am J Clin Nutr 1982; 35:697-700.
12. Kalliomäki JL, Waris EK, Vasama R. Sitosterolemas verkan på blodets kolesterol och lipoproteiner. Nord Med 1957; 57:460-463.
13. Bhattacharyya AK, Conner WE. β-Sitosterolemia and xanthomatosis. A newly described lipid storage disease in two sisters. J Clin Invest 1974; 53:1033-1043.
14. Grundy SM, Ahrens EH Jr, Davignon J. The interaction of cholesterol absorption and synthesis in man. J Lipid Res 1969; 10:304-315.
15. Jones PJH, Howell T, MacDougall DE, Feng JY, Parsons W. Short-termadministration of tall oil phytosterols improves plasma lipid profiles in subjectswith different cholesterol levels. Metabol Clin Exp 1998; 47:751-756. A plant sterol mixture, containing sitosterol, sitostanol, campesterol and campestanol (62%, 21%, 16% and 1%, respectively) were fed (21.2 mg/kg) in mostly insoluble form to normocholesterolemic individuals for 10 days. Total cholesterol was significantly decreased to 4.7 ± 0.3 mmol/l from 5.0 ± 0.3 mmol/l, and LDL cholesterol to 3.0 ± 0.3 mmol/l from 3.2 ± 0.3 mmol/l by tall oil sterols versus placebo. Plant sterol/cholesterol ratios were not changed and cholesterol synthesis appeared to increase only in individuals with a low baseline cholesterol level.
16. Howell TJ, MacDougall DE, Jones PJH. Phytosterols partially explain differences in cholesterol metabolism caused by com or olive oil. J Lipid Res 1998; 39:892-900.
17. Weststrate JA, Meijer GW. Plant sterol-enriched margarines and reduction ofplasma total- and LDL-cholesterol concentrations in normocholesterolaemic and mildly hypercholesterolaemic subjects. Eur J Clin Nutr 1998; 52:334-343. Serum cholesterol was significantly decreased by plant sterol and stanol feeding. Cholesterol lowering was associated with increased serum plant sterol levels in sterol-fed individuals but decreased plant sterol concentrations in stanol-fed individuals.
18. Richter WO, Geiss HC, Sönnichsen AC, Schwandt P. Curr Ther Res 1996; 57:497-505.
19. Pelletier X, Belbraouet S, Mirabel D, Mordret F, Perrin JL, Pages X, Debry G. A diet moderately enriched in phytosterols lowers plasma cholesterol concentrations in normocholesterolemic humans. Ann Nutr Metab 1995; 35:291-295.
20. Sugano M, Kamo F, Ikeda I, Morioka H. Lipid-lowering activity of phytostanols in rats. Atherosclerosis 1976; 24:301-309.
21. Sugano M, Morioka H, Ikeda I. A comparison of hypocholesterolemic activity of β-sitosterol and β-sitostanol in rats. J Nutr 1977; 107:2011-2019.
22. Ikeda I, Kawasaki A, Samezima K, Sugano M. Antihypercholesterolemic activity of S-sitostanol in rabbits. J Nutr Sci Vitaminol 1981; 27:243-251.
23. Ikeda I, Sugano M. Comparison of absorption and metabolism of beta-sitosterol and beta-sitostanol in rats. Atherosclerosis 1978; 30:227-237.
24. Heinemann T, Leiss O, von Bergmann K. Effect of low-dose sitostanol on serum cholesterol in patients with hypercholesterolemia. Atherosclerosis 1986, 61:219-223.
25. Becker M, Staab D, von Bergmann K. Treatment of severe familial hypercholesterolemia in childhood with sitosterol and sitostanol. J Pediatr 1993; 122:292-296.
26. Heinemann T, Kullak-Ublick G-A, Pietruck B, von Bergmann K. Mechanisms of action of plant sterols on inhibition of cholesterol absorption. Comparison of sitosterol and sitostanol. Eur J Clin Pharmacol 1991; 40 (Suppl 1):S59-S63.
27. Heinemann T, Axtmann G, von Bergmann K. Comparison of intestinal absorption of cholesterol with different plant sterols in man. Eur J Clin Invest 1993; 23:827-831.
28. Denke MA. Lack of efficacy of low-dose sitostanol therapy as an adjunct to a cholesterol-lowering diet in men with moderate hypercholesterolemia. Am J Clin Nutr 1994; 61:392-396.
29. Miettinen TA, Vanhanen H. Dietary sitostanol related to absorption, synthesis and serum level of cholesterol in different apolipoprotein E phenotypes. Atherosclerosis 1994; 105:217-226.
30. Vanhanen HT, Blomqvist S, Ehnholm C, Hyvijnen M, Jauhiainen M, Torstila I, Miettinen TA. Serum cholesterol, cholesterol precursors, and plant sterols in hypercholesterolemic subjects with different apoE phenotypes during dietary sitostanol ester treatment. J Lipid Res 1993; 34:1535-1544.
31. Gylling H, Miettinen TA. Cholesterol lowering by different plant stanol mixturesand on variable fat intake. Metabol Clin Exp 1998; (in press). The feeding of stanol esters in margarines with variable campestanol contents similarly lowered serum cholesterol both on unsaturated and butter-saturated margarines. Serum plant sterol/cholesterol ratios were decreased, but a small respective increase of plant stanols, was observed.
32. Vanhanen HT, Kajander J, Lehtovirta H, Miettinen TA. Serum levels, absorption efficiency, faecal elimination and synthesis of cholesterol during increasing doses of dietary sitostanol esters in hypercholesterolaemic subjects. Clin Sci 1994; 87:61-67.
33. Gylling H, Miettinen TA. Sitostanol ester added to long term simvastatin treatment of coronary patients with low and high basal cholesterol absorption. Atherosclerosis 1997; 134:157.
34. Gylling H, Siimes M, Miettinen TA. Sitostanol ester margarine in dietary hypolipidemic treatment of children with familial hypercholesterolemia. J Lipid Res 1995; 36:1807-1812.
35. Vuorio AF, Gylling H, Turtola H, Kontula K, Miettinen TA. Sitostanol estermargarine without and with simvastatin in dietary treatment of families heterozygous of familial hypercholesterolemia North Karelia deletion. Circulation 1998; 98:1533-1534. Twenty-four children with familial hypercholesterolemia North Karelia (FH-NK) deletion, four parents with FH-NK, 16 nonaffected family members and 12 FH-NK adults with simvastatin treatment consumed stanol ester margarine for 3 months. LDL cholesterol was reduced significantly by 17%, 12% (NS), 13% and 20% in the four groups, respectively. HDL cholesterol and serum triglycerides were unchanged. Serum plant sterol/cholesterol ratios were significantly decreased.
36. Tammi A, Rönnemaa T, Gylling H, Pulkki K, Simell O and the STRIP StudyGroup. The effect of sitostanol ester margarine on serum lipids in healthy children already on a diet low in saturated fat and cholesterol. The STRIP Project. 70th EAS Congress; 6-9 September 1998; Geneva, Switzerland (abstract). p. 28. Seventy-two healthy, normolipidemic 6-year-old children on a low-fat low cholesterol diet consumed sitostanol ester margarine for 3 months (1.46 g stanols/day) Total and LDL cholesterol levels were significantly diminished without any change in HDL cholesterol, triglycerides or safety markers.
37. Niinikoski H, Viikari J, Palmu T. Cholesterol-lowering effect and sensoryproperties of sitostanol ester margarine in normocholesterolemic adults. ScandJ Nutr 1997; 41:9-12. This study revealed that sitostanol ester margarine lowered total and LDL cholesterol levels effectively in normocholesterolemic adults.
38. Gylling H, Miettinen TA. Serum cholesterol and cholesterol and lipoprotein metabolism in hypercholesterolaemic NIDDM patients before and during sitostanol ester-margarine treatment. Diabetologia 1994; 37:773-780.
39. Gylling H, Miettinen TA. The effects of inhibiting cholesterol synthesis and absorption on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin dependent diabetic men. J Lipid Res 1996; 31:1776-1785.
40. Gylling H, Miettinen TA. The effect of cholesterol absorption inhibition on low density lipoprotein cholesterol level. Atherosclerosis 1995; 117:305-308.
41. Thompson GR, Naoumova RP, Watts GF. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res 1996; 37:439-447.
42. Berglund L, Witztum JL, Galeano NF, Khouw AS, Ginsberg HN, Ramakrishnam R. Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for receptor. Results from a novel triple-tracer approach. J Lipid Res 1998; 39:913-924.
43. Himber J, Missano B, Rudling UH, Kempen HJ. Effects of stigmastanyl-phosphocholin (Ro-16-6532) and lovastatin on lipid and lipoprotein levels and lipoprotein metabolism in the hamster on different diets. J Lipid Res 1995; 36:1567-1585.
44. Miettinen TA, Gylling H, Puska P, Vanhanen H, Vartiainen E. A long-term population study of cholesterol lowering by sitostanol ester margarine. Circulation 1995; 92:1799.
45. Gylling H, Puska P, Vartiainen E, Miettinen TA. Serum retinol, α-tocopherol, carotenes and lipid peroxidation during two-year sitostanol ester treatment in a hypercholesterolemic population. Circulation 1996; 94 (Suppl 1):3379.
46. Gylling H, Rajaratnam R, Miettinen TA. Reduction of serum cholesterol in postmenopausal coronary women with dietary sitostanol ester margarine.Circulation 1997; 96:4226-4231. In 22 postmenopausal women with coronary artery disease and on a low cholesterol and fat diet, sitostanol ester margarine (3 g stanol/day) reduced total and LDL cholesterol levels significantly by 13% and 20% from home values. None of the women had LDL cholesterol levels below 100 mg/dl (2.6 mmol/l) during home diet compared with 32% of individuals during sitostanol ester margarine use. In another group of 10 postmenopausal coronary women taking simvastatin, the combination of sitostanol ester margarine to simvastatin reduced total and LDL cholesterol by 11% and 16%, respectively, from simvastatin only period. This observation suggests that the combination of stanol ester and statin therapy potentiates the lipid-lowering effect.
47. Miettinen TA, Gylling H, Strandberg T, Sarna S, for the Finnish 4S Investigators. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian Simvastatin Survival Study. BMJ 1998; 316:1127-1130.
48. Miettinen TA, Gylling H. Basal non-cholesterol sterols reveal a subgroup of 43 not benefitted by simvastatin-induced decrease of recurrent coronary events. Atherosclerosis 1997; 134:48.
49. Miettinen TA, Gylling H. Are increased plant sterols or reduced cholesterollowering in serum by simvastatin responsible for lacking decrease of coronary events in coronary subjects? 70th EAS Congress; 6-9 September 1998; Geneva, Switzerland (abstract). p. 78. Sitostanol ester margarine lowers serum cholesterol more consistently inindividuals with expected high than low cholesterol absorption during simvastatintreatment.
50. Lutjohann D, von Bergmann K. Phytosterolaemia: diagnosis, characterization and therapeutic approaches. Ann Med 1997; 29:181-184.
51. Vanhanen H. Cholesterol malabsorption caused by sitostanol ester feeding and neomycin in pravastatin-treated hypercholesterolaemic patients. Eur J Clin Pharmacol 1994; 47:169-176.
52. Gylling H, Miettinen TA. Lipid lowering by inhibition of synthesis and absorptionof cholesterol during bile acid binding resin. 70th EAS Congress; 6-9September 1998; Geneva, Switzerland (abstract). p. 157. The concurrent use of sitostanol eater margarine, statin and bile acid binding resin potentiates the cholesterol-lowering effect.
53. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308:367-372.
54. Ntanios FY, Jones PJH, Frohlich JJ. Dietary sitostanol reduces plaque formation but not lecithin cholesterol acyl transferase activity in rabbits. Atherosclerosis 1998; 138:101-110.